147 related articles for article (PubMed ID: 30578577)
21. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
[TBL] [Abstract][Full Text] [Related]
22. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
23. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
Merouani A; Davidson SA; Schrier RW
Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
[TBL] [Abstract][Full Text] [Related]
24. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
[TBL] [Abstract][Full Text] [Related]
25. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
Schiller JH; Storer B; Berlin J; Wittenkeller J; Larson M; Pharo L; Larson M; Berry W
J Clin Oncol; 1996 Jun; 14(6):1913-21. PubMed ID: 8656260
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
[TBL] [Abstract][Full Text] [Related]
27. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Giaccone G; Splinter TA; Debruyne C; Kho GS; Lianes P; van Zandwijk N; Pennucci MC; Scagliotti G; van Meerbeeck J; van Hoesel Q; Curran D; Sahmoud T; Postmus PE
J Clin Oncol; 1998 Jun; 16(6):2133-41. PubMed ID: 9626213
[TBL] [Abstract][Full Text] [Related]
28. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.
Patimarattananan T; Nongnuch A; Pattaranutaporn P; Unwanatham N; Jiarpinitnun C; Ngamphaiboon N
Support Care Cancer; 2021 Feb; 29(2):877-887. PubMed ID: 32524284
[TBL] [Abstract][Full Text] [Related]
29. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.
Faig J; Haughton M; Taylor RC; D'Agostino RB; Whelen MJ; Porosnicu Rodriguez KA; Bonomi M; Murea M; Porosnicu M
Am J Clin Oncol; 2018 May; 41(5):432-440. PubMed ID: 27281266
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of 72-hour continuous infusion consisting of cisplatin and 5-fluorouracil for treatment of non-small cell lung cancer.
Tsuchiya S; Minato K; Nakano H; Takise A; Ezawa K; Fueki N; Hoshino H; Naruse I; Takei Y; Makimoto T
Oncology; 1995; 52(3):246-50. PubMed ID: 7715909
[TBL] [Abstract][Full Text] [Related]
31. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
32. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: which dose is more suitable?
Ilhan Y; Onder AH; Ozbay MF; Karakaya G; Sezgin Goksu S; Ozturk B; Coskun HS
Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3403-3413. PubMed ID: 38766796
[TBL] [Abstract][Full Text] [Related]
33. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.
Fokkema E; de Vries EG; Meijer S; Groen HJ
Cancer Chemother Pharmacol; 2000; 45(1):89-92. PubMed ID: 10647508
[TBL] [Abstract][Full Text] [Related]
34. Four-day paclitaxel infusion with cisplatin for patients with lung cancer.
Georgiadis MS; Schuler B; Johnson BE
Semin Oncol; 1995 Aug; 22(4 Suppl 9):67-9. PubMed ID: 7544027
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients.
Toprak Z; Cebeci E; Helvaci SA; Toprak ID; Kutlu Y; Sakin A; Tukek T
Int Urol Nephrol; 2017 Jun; 49(6):1041-1047. PubMed ID: 28255639
[TBL] [Abstract][Full Text] [Related]
36. A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
Dhillon P; Amir E; Lo M; Kitchlu A; Chan C; Cochlin S; Yip P; Chen E; Lee R; Ng P
J Oncol Pharm Pract; 2019 Jun; 25(4):875-883. PubMed ID: 29722605
[TBL] [Abstract][Full Text] [Related]
37. Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study.
Lin CL; Chien RN; Yeh C; Hsu CW; Chang ML; Chen YC; Yeh CT
Scand J Gastroenterol; 2014 Dec; 49(12):1456-64. PubMed ID: 25283499
[TBL] [Abstract][Full Text] [Related]
38. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery.
Hakeam HA; Breakiet M; Azzam A; Nadeem A; Amin T
Ren Fail; 2014 Nov; 36(10):1486-91. PubMed ID: 25155314
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
40. [Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Zhang P; Feng FY; Wu LY; Hu Y; Liu JW; Gao YJ; Guan XQ; Nan KJ; Suo AL; Wang XW; Zhang MH; Zhang WD; Li CW; Zhang Y; Zhao JB
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):230-4. PubMed ID: 16875614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]